Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL11548600 | 0.86 | LMNA (0.52) | LMNACYP1A2MEN1KMT2AALDH1A1 | |
| Butanone SCHEMBL9440666 | 0.81 | LMNA (0.57) | LMNAALDH1A1 | |
| Acetone SCHEMBL3833129 | 0.81 | LMNA (0.63) | LMNAALDH1A1 | |
| Ethylene SCHEMBL11223309 | 0.81 | LMNA (0.46) | LMNAALDH1A1 | |
| SCHEMBL21768046 | 0.79 | LMNA (0.55) | LMNAALDH1A1 | |
| SCHEMBL27986820 | 0.78 | LMNA (0.52) | LMNAALDH1A1 | |
| Acetamide SCHEMBL6279784 | 0.77 | LMNA (0.63) | LMNACYP1A2MEN1KMT2AALDH1A1 | |
| Butanone SCHEMBL3163812 | 0.77 | LMNA (0.63) | LMNAALDH1A1 | |
| Acetone SCHEMBL590699 | 0.76 | LMNA (0.71) | LMNAALDH1A1 | |
| Levulinic Acid SCHEMBL6535100 | 0.76 | LMNA (0.58) | LMNACYP1A2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117562-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2117535-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | GLAXO GROUP LIMITED | 2010-12-16 | — | — | US | disclosed |
| US-20100152446-A1 | Piperidine Derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| EP-1921064-B1 | Pharmaceutical composition | GLAXO GROUP LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100081667-A1 | Chemical Compounds | ALVARO GIUSEPPE | 2010-04-01 | — | — | US | disclosed |
| US-7652012-B2 | Orvepitant maleate; potent and specific antagonists of tachykinins, including substance P and other neurokinins; anxioltic and antidepressant | GLAXO GROUP LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7648990-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| EP-1472256-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1326832-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-10-06 | — | — | EP | disclosed |
| US-20040014770-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | US | disclosed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003066635-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066589-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066621-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| EP-1326832-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002032867-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | LMNA 2983/4885PAOX 3976/4885CYP1A2 973/4885 |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | TACR2, TACR1, KCNH3 | LMNA 2179/4885PAOX 3826/4885CYP1A2 1100/4885 |
| US-20040014770-A1 | Chemical compounds | HCK, KCNK4, GRK4 | LMNA 3453/4885PAOX 4593/4885CYP1A2 1055/4885 |
| US-20100152446-A1 | Piperidine Derivatives | NPSR1, NPY5R, NPY4R | LMNA 4022/4885PAOX 1370/4885CYP1A2 1845/4885 |
| US-20100081667-A1 | Chemical Compounds | OPRL1, OPRK1, OPRM1 | LMNA 4408/4885PAOX 977/4885CYP1A2 119/4885 |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | HTR1A, TPH1, HTR5A | LMNA 3142/4885PAOX 4727/4885CYP1A2 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.